Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5925876 | 0.80 | NOS3 (0.36) | NOS3NOS1NOS2KMT2AHSP90AA1 | |
| SCHEMBL30743598 | 0.80 | NOS3 (0.36) | NOS3NOS1NOS2KMT2AHSP90AA1 | |
| SCHEMBL23380788 | 0.79 | KMT2A (0.36) | NOS3NOS1NOS2KMT2AHSP90AA1 | |
| Hydrochloric Acid SCHEMBL22031716 | 0.79 | NOS3 (0.35) | NOS3NOS1NOS2KMT2AHSP90AA1 | |
| SCHEMBL5742622 | 0.77 | GRM5 (0.41) | NOS3NOS1NOS2HSP90AA1ALDH1A1 | |
| SCHEMBL23704358 | 0.77 | NOS3 (0.45) | NOS3NOS1NOS2HSP90AA1MAPT | |
| SCHEMBL29994138 | 0.77 | NOS3 (0.45) | NOS3NOS1NOS2HSP90AA1MAPT | |
| SCHEMBL3883842 | 0.76 | MAPT (0.52) | KMT2AMAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL3765744 | 0.76 | — | — | |
| SCHEMBL30038734 | 0.75 | AXL (0.33) | NOS3NOS1NOS2KMT2AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958873-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20220298181-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11242361-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242361-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| WO-2015073528-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073528-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-9029536-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NOS3 3535/4885NOS1 3241/4885NOS2 3670/4885 |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NOS3 3535/4885NOS1 3241/4885NOS2 3670/4885 |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE10A, PDE3A, PDE2A | NOS3 504/4885NOS1 267/4885NOS2 480/4885 |
| US-20220298181-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NOS3 3535/4885NOS1 3241/4885NOS2 3670/4885 |
| US-11242361-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | NOS3 3535/4885NOS1 3241/4885NOS2 3670/4885 |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NOS3 3535/4885NOS1 3241/4885NOS2 3670/4885 |
| US-11958873-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | NOS3 3535/4885NOS1 3241/4885NOS2 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.